Replies to post #7870 on Revive Therapeutics Ltd (RVVTF)

[Giovanni]

This is one of them

Sarilumab
Pharmaceutical
Description
DescriptionSarilumab is a human monoclonal antibody against the interleukin-6 receptor. Regeneron Pharmaceuticals and Sanofi developed the drug for the treatment of rheumatoid arthritis, for which it received US FDA approval on 22 May 2017 and European Medicines Agency approval on 23 June 2017. Wikipedia
Bioavailability: 80%
Target: IL-6R
Elimination half-life: 21 days (steady-state, estimated)
Formula: C6388H9918N1718O1998S44